Sofia Reis de Oliveira Crispim

Targeted therapies and immunotherapies in the treatment of triple-negative breast cancer

Introduction: Triple-negative breast cancer (TNBC) accounts for 10–15% of cases and is characterized by the absence of hormone receptors and low HER2 expression, which limits the use of endocrine or anti-HER2 therapies. It is an aggressive subtype, usually associated with poorer prognosis than other breast cancers. Sin...